RadNet buys nine centers, sells one
FDA clears Ziehm mobile C-arm
RadNet buys nine centers, sells one
No sooner had RadNet completed its two-month-old deal to acquire nine New Jersey imaging centers than the company began whittling down the purchase price, turning new assets into hard cash. RadNet sold off a single-modality open MRI center in southern New Jersey, along with some legacy image management systems, for $650,000, thus retrieving a chunk of the $2.1 million paid to Medical Resources for the nine facilities. Tristate Imaging bought the center, which RadNet described as being outside the market served by the closest RadNet centers. The acquisition price will drop further if RadNet sells, as planned, a building in Union, NJ, that it acquired in the deal. The Medical Resources acquisition is part of a strategy to connect RadNet's Mid-Atlantic and southern New York operations. These complement core operations in California, Maryland, and Delaware. All told, RadNet operates a network of 175 fully owned and operated outpatient imaging centers.
FDA clears Ziehm mobile C-arm
The FDA has cleared the Vision RFD, a mobile C-arm from Ziehm Imaging. The compact system is designed for use in endovascular surgery, interventional cardiology, and interventional radiology. It features a flat-panel sensor as part of its digital imaging chain. A large C-arm opening and 165º orbital rotation allow easy patient access.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
